Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter European Pilot Study of 90Yttrium-Ibritumomab Tiuxetan as First Line Therapy for Stage III - IV Follicular Lymphoma (and Selected Patients With Extended Stage II) Followed by Consolidation Rituximab for Patients in Complete Remission But With Persistent Molecular Disease

NCT00772655 is registered in ClinicalTrials.gov with Charite University, Berlin, Germany as lead sponsor.

NCT NCT00772655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00772655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter European Pilot Study of 90Yttrium-Ibritumomab Tiuxetan as First Line Therapy for Stage III - IV Follicular Lymphoma (and Selected Patients With Extended Stage II) Followed by Consolidation Rituximab for Patients in Complete Remission But With Persistent Molecular Disease
Lead sponsor
Charite University, Berlin, Germany
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2007
Completion date
June 30, 2015
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma